Lorlatinib in previously treated anaplastic lymphoma kinase‐rearranged non–small cell lung cancer: Japanese subgroup analysis of a global study

Lorlatinib is a potent, brain‐penetrant, third‐generation anaplastic lymphoma kinase (ALK)/ROS proto‐oncogene 1 (ROS1) tyrosine kinase inhibitor (TKI) that is active against most known resistance mutations. This is an ongoing phase 1/2, multinational study (NCT01970865) investigating the efficacy, s...

Descripción completa

Detalles Bibliográficos
Autores principales: Seto, Takashi, Hayashi, Hidetoshi, Satouchi, Miyako, Goto, Yasushi, Niho, Seiji, Nogami, Naoyuki, Hida, Toyoaki, Takahashi, Toshiaki, Sakakibara‐Konishi, Jun, Morise, Masahiro, Nagasawa, Takashi, Suzuki, Mie, Ohkura, Masayuki, Fukuhara, Kei, Thurm, Holger, Peltz, Gerson, Nishio, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540988/
https://www.ncbi.nlm.nih.gov/pubmed/32681682
http://dx.doi.org/10.1111/cas.14576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540988/
https://www.ncbi.nlm.nih.gov/pubmed/32681682
http://dx.doi.org/10.1111/cas.14576

Ejemplares similares